Finance
France’s Carmat Files for Insolvency, Shares Suspended
Published by Global Banking & Finance Review®
Posted on June 30, 2025
1 min readLast updated: January 23, 2026
Add as preferred source on GoogleGlobal Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on June 30, 2025
1 min readLast updated: January 23, 2026
Add as preferred source on GoogleCarmat, a French heart prosthesis firm, filed for insolvency after failing to secure emergency funding, suspending its shares. A court decision is pending.
(Reuters) -French heart prosthesis company Carmat has filed for insolvency and requested to be placed in receivership after failing to secure emergency funding, it said on Monday.
Trading in Carmat shares have been suspended at the company's request, it said, pending a decision by the the Versailles Economic Affairs Court.
Carmat, which had warned earlier this month that it could run out of cash by end-June without fresh financing, said it had not managed to raise the 3.5 million euros ($4.1 million) it needed and had submitted the filing to the court.
The group said it would require 35 million euros over the next 12 months under its current business plan, including 20 million euros by the end of 2025.
A court hearing is expected in the coming days, Carmat added.
($1 = 0.8522 euros)
(Reporting by Anna Peverieri; Editing by Matt Scuffham)
Carmat filed for insolvency after failing to secure emergency funding and warned it could run out of cash by the end of June without fresh financing.
Trading in Carmat shares has been suspended at the company's request, pending a decision by the Versailles Economic Affairs Court.
Carmat stated it would require 35 million euros over the next 12 months, including 20 million euros by the end of 2025.
A court hearing regarding Carmat's insolvency is expected in the coming days.
Explore more articles in the Finance category